Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Malignant Neoplasm of Liver
Interventions
DRUG

68Ga-aGPC3-scFv/Fab

"For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."

Trial Locations (1)

430022

RECRUITING

China, Hubei Province, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER